Hartfalen: epidemiologie, risicofactoren en toekomst

RIVM Rapport 260401006
Djoussé L, Driver JA, Gaziano JM (2009). Relation between modifiable lifestyle
factors and lifetime risk of heart failure. JAMA 302, 394-400.
Drazner MH (2011). The progression of hypertensive heart disease. Circulation
123(3): 327-334.
Dunlay SM, Weston SA, Jacobsen SJ, Roger VL (2009). Risk factors for heart
failure: a population-based case-control study. Am J Med 122: 1023-8.
Dupree CS (2009). Primary prevention of heart failure: what is the evidence?
Curr Opin Cardiol 24(2): 142-7.
Egan BM, Zhao YZ, Axon RN (2010). US trends in prevalence, awareness,
treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-
2050.
Eggers KM, Lind L, Ahlström H, Bjerner J, Ebeling Barbier C, Larsson A, Venge P,
Lindahl B (2008). Prevalence and pathophysiological mechanisms of elevated
cardiac troponin I levels in a population-based sample of elderly subjects. Eur
Heart J 29(18): 2252-2258.
Emdin M, Vittorini S, Passino C, Clerico A (2009). Old and new biomarkers of
heart failure. Eur J Heart Fail 11, 331-5.
Engelfriet PM, Hoogenveen RT, Boshuizen HC, van Baal PH (2011). To die with
or from heart failure: a difference that counts. Eur J Heart Fail 13(4):377-83.
Engström G, Hedblad B, Tyden P, Lindgarde F (2009). Inflammation-sensitive
plasma proteins are associated with increased incidence of heart failure: a
population-based cohort study. Atherosclerosis 202, 617-22.
European Society of Cardiology (2008). ESC Guideline for the diagnosis and
treatment of acute and chronic heart failure 2008. Eur Heart J
2008;29:2388-2442.
Fertin M, Hennache B, Hamon M, Ennezat PV, Biausque F, Elkohen M, Nugue O,
Tricot O, Lamblin N, Pinet F, Bauters C (2010). Usefulness of serial
assessment of B-type natriuretic peptide, troponin I, and C-reactive protein
to predict left ventricular remodeling after acute myocardial infarction (from
the REVE-2 study). Am J Cardiol 106, 1410-6.
Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer S,
Doring A, Broeckel U, Riegger G, Schunkert H (2003). Prevalence of left
ventricular diastolic dysfunction in the community. Results from a Doppler
echocardiographic-based survey of a population sample. Eur Heart J 24, 320-
8.
Folsom AR, Yamagishi K, Hozawa A, Chambless LE (2009). Absolute and
attributable risks of heart failure incidence in relation to optimal risk factors.
Circ Heart Fail 2, 11-7.
Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH,
Capewell S (2007). Explaining the decrease in U.S. deaths from coronary
disease, 1980-2000. N Engl J Med 356, 2388-98.
Fox CS, Evans JC, Larson MG, Kannel WB, Levy D (2004). Temporal trends in
coronary heart disease mortality and sudden cardiac death from 1950 to
1999: the Framingham Heart Study. Circulation 110, 522-7.
Fox KF, Cowie MR, Wood DA, Coats AJ, Gibbs JS, Underwood SR, Turner RM,
Poole-Wilson PA, Davies SW, Sutton GC (2001). Coronary artery disease as
the cause of incident heart failure in the population. Eur Heart J 22, 228-36.
Fox KM. (2003). Efficacy of perindopril in reduction of cardiovascular events
among patients with stable coronary artery disease: randomised, doubleblind,
placebo-controlled, multicentre trial (the EUROPA study). Lancet
362(9386): 782-8.
Frazier CG, Alexander KP, Newby LK, Anderson S, Iverson E, Packer M, Cohn J,
Goldstein S, Douglas PS (2007). Associations of gender and etiology with
outcomes in heart failure with systolic dysfunction: a pooled analysis of 5
randomized control trials. J Am Coll Cardiol 49, 1450-8.
Pagina 100 van 122